Clene Stock (NASDAQ:CLNN), Trade Ideas

Clene

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ASML

CHRO

CLNN

CXAI

DFLI

DXYZ

DYNT

GPAK

INVO

JBHT

MGAM

PACB

SXTC

TPET

VIAO

WISA

YYAO

Shares of  INVO Bioscience, Inc. (NASDAQ: INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results.

Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket

Intraday Update

ABNB

AKAM

ALSN

ANGI

AZTR

BGLC

BLNK

CART

CCTG

CEVA

CNVS

COGT

COIN

DTSS

EEIQ

ELWS

ENGN

GLDD

GMBL

HCSG

HOOD

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

IREN

KTOS

Larimar Therapeutics, Inc. - Common Stock

LRMR

LYFT

MGOL

NUKK

QDEL

QRTEB

REZI

SNTG

Sony Group Corporation American Depositary Shares

SONY

SUNW

TSEM

UFCS

UPST

VBIV

Shares of  Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list its financial arm in October 2025.

Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

ANNX

HOOK

LGVN

PBLA

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday.

The Dow traded up 0.37% to 37,218.15 while the NASDAQ rose 0.73% to 14,885.76. The S&amp;P 500 also rose, gaining, 0.50% to 4,721.72.

Nasdaq Gains 100 Points; CarMax Earnings Top Views

Clene Inc

Morgan Stanley analyst James Faucette upgrades EPAM Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) from Underweight to Equal-Weight and lowers the price target from $236 to $225.

Upgrades

Price Target

Analyst Ratings

EPAM

Morgan Stanley Upgrades EPAM Sys to Equal-Weight, Lowers Price Target to $225

RBC Capital analyst Scott Hanold downgrades Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) from Outperform to Sector Perform and raises the price target from $36 to $39.

Downgrades

RBC Capital Downgrades Range Resources to Sector Perform, Raises Price Target to $39

The U.S. Supreme Court, which deliberated former <a href="https://www.benzinga.com/news/24/04/38449386/supreme-court-justices-weigh-absolute-immunity-for-trump-lean-toward-some-protection-we-have-seen-th">Donald Trump&#8217;s immunity claims</a> on Thursday, ruled that former presidents enjoy some degree of immunity from criminal prosecution, and two legal experts weighed in on the proceedings in the apex court.
Chief Justice Holds The Key: Four Justices of the nine-member bench will likely reject claims about Trump&#8217;s absolute immunity and this shifts the spotlight to Chief Justice John Roberts Jr., <a href="https://www.youtube.com/watch?v=sVaoJuvQE_w">said</a> Neel Katyal, an American appellate lawyer and professor of law, in an MSNBC interview.
The question is whether there would be a fifth vote and that would be the chief justice, he said, adding that the top justice was quieter during the hearing.
&#8220;But the chief justice does have [the] ability to surprise us,&#8221; Katyal said, adding that he was the fifth voter who upheld President Barack Obama&#8217;s Affordable Care Act right before the 2012 election.
&#8220;I hold out hope the chief will do the right thing here, uphold the rule of law and reject Trump&#8217;s claims of absolute immunity and let this trial go on so the American people can see it for themselves,&#8221; the legal expert said.
See Also: <a href="https://www.benzinga.com/news/24/04/38348880/donald-trump-could-still-win-even-if-he-loses-in-supreme-court-over-presidential-immunity-claim">Donald Trump Could Still Win Even If He Loses In Supreme Court Over Presidential Immunity Claim</a>
Shocking, Says Weissmann: Former DOJ Attorney and law professor Andrew Weissmann concurred with Katyal that it is going to come down to the chief justice.
&#8220;This is the chance to do something but this decision, just remember, no one was arguing that private acts are either civilly or criminally immune. Everyone agrees private acts you can always be prosecuted for so that&#8217;s a given,&#8221; he said.
So, it was not a win for Special Counsel Jack Smith, who is leading the prosecution side in Trump&#8217;s classified documents case, Weissmann said.
&#8220;I was just shocked that democracy as we know, is riding on finding that fifth vote. There should not be any justices who are in any way supporting this idea,&#8221; the DOJ veteran said. 
It could be like five, four, one way or the other on the case, Weissmann said. This tells you &#8220;how inured we are to the sort of Trumpism overtaking what this country is supposed to stand for,&#8221; he added.
Read Next: <a href="https://www.benzinga.com/money/how-to-invest-in-startups">How To Invest In Startups</a>
Photo courtesy: Shutterstock

Politics

Legal

Media

'Just Shocked:' DOJ Veteran Says Potential SCOTUS Suprise Over Trump's Immunity Claim Shows 'How Inured We Are To Sort Of Trumpism Overtaking What This Country Is Supposed To Stand For'

Morgan Stanley analyst Erin Wright downgrades Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) from Overweight to Equal-Weight and lowers the price target from $33 to $21.

NVST

Morgan Stanley Downgrades Envista Holdings to Equal-Weight, Lowers Price Target to $21

Needham analyst Kyle Peterson reiterates Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Buy and maintains $1500 price target.

Reiteration

FICO

Needham Reiterates Buy on Fair Isaac, Maintains $1500 Price Target

<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38085675/were-fd-says-rich-dad-poor-dad-author-robert-kiyosaki-because-fed-chair-powell-fina" rel="noreferrer noopener">Robert Kiyosaki</a>, the author of the best-selling book &#8220;Rich Dad Poor Dad,&#8221; believes the U.S. economy is definitely in a state of depression.
What Happened: On Friday, Kiyosaki took to X, to express his view on the state of the U.S. economy. He stated that the economy was in a state of depression because it was experiencing subpar growth.
He wrote, &#8220;Q: Is the American economy in DEPRESSION? A: Yes Definition of a depression: an economy in subpar growth. In other words, the economy may be growing but below potential.&#8221;
Kiyosaki pointed out that the U.S. economy, which grew by 3.4% in the fourth quarter of 2023, only grew by 1.6% in the first quarter of 2024, less than half of the previous quarter&#8217;s growth.
He warned that this trend does not indicate a soft landing and urged people to seek the facts, prepare, and take care.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Q: Is the American economy in DEPRESSION? A: Yes Definition of a depression: an economy in subpar growth. In other words the economy may be growing but below potential. Q4 2023 economy grew by 3.4%. Q1 2024 economy grew by 1.6% less than half. Not going to be a soft…
&mdash; Robert Kiyosaki (@theRealKiyosaki) <a href="https://twitter.com/theRealKiyosaki/status/1783602546235318453?ref_src=twsrc%5Etfw">April 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38374783/wall-street-set-to-open-higher-as-tesla-to-kick-off-magnificent-7-earnings-why-this-analyst-thinks-?itm_source=parsely-api" rel="noreferrer noopener">S&amp;P 500, Nasdaq Futures Climb Higher: Will Tesla Earnings Spark Rally Or Retreat?</a>
Why It Matters: Kiyosaki&#8217;s warning, although technically incorrect, comes at a time when the U.S. economy is facing various challenges. 
According to the Federal Reserve Bank of San Francisco, a depression is an extreme form of recession lasting three or more years or resulting in a GDP decline of at least 10% in a given year. Throughout its history, the U.S. has faced 34 recessions, including notable ones like the Great Recession of 2008-2009 and the COVID-19 recession of 2020. However, it has experienced only one depression, famously known as the Great Depression, spanning from 1929 to 1941.
Early 2022 had two consecutive quarters of negative GDP growth. That's the&nbsp;<a target="_blank" href="https://www.benzinga.com/economics/23/11/35978120/why-havent-we-had-a-recession-yet-deep-knowledge-investing-research-on-the-economy" rel="noreferrer noopener">definition of a recession</a>.&nbsp;However, the&nbsp;National Bureau of Economic Research&nbsp;declined to declare that there was a recession due to other technical indicators.
The Federal Reserve&#8217;s signals to&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/04/38425604/feds-high-interest-rate-policy-spurs-debate-over-economic-impact-this-is-the-path-of-a-potential-pro" rel="noreferrer noopener">maintain&nbsp;high interest</a>&nbsp;rates have sparked concerns about its potential impact on the economy. Despite the ongoing economic stability, the Fed&#8217;s stance has raised questions about its potential impact on the economy.
Additionally,&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38109673/top-economist-flags-warning-signs-of-possible-recession-in-us-economy-it-certainly-" rel="noreferrer noopener">warning signs of a possible recession</a>&nbsp;have been flagged by top economists. The Economic Cycle Research Institute&#8217;s leading economic index, known for its near-perfect track record, has been on a downward trend for the past year. Despite a recent leveling off, past patterns suggest that a dip in this index often precedes a recession.
Read Next: <a href="https://www.benzinga.com/economics/macro-economic-events/24/04/38410454/treasury-yields-reach-5-month-high-lift-mortgage-rates-expert-warns-federal-debt-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Treasury Yields Reach 5-Month High, Lift Mortgage Rates; Expert Warns &#8216;Federal Debt Blob Is Out Of Control&#8217;</a>
Image by Gage Skidmore via Flickr
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Kaustubh Bagalkote</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/topic/kaustubh-bagalkote" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Social Media

Economics

'Rich Dad Poor Dad' Author Robert Kiyosaki Believes US Economy Is 'In Depression' And Warns It's 'Not Going To Be A Soft Landing'

Needham analyst Ryan MacDonald reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold.

TDOC

Needham Reiterates Hold on Teladoc Health

Needham analyst Joshua Reilly reiterates Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) with a Buy and maintains $500 price target.

Needham Reiterates Buy on Tyler Technologies, Maintains $500 Price Target

Piper Sandler analyst Brent Bracelin reiterates Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Overweight and raises the price target from $455 to $465.

MSFT

Piper Sandler Reiterates Overweight on Microsoft, Raises Price Target to $465

Needham analyst Quinn Bolton reiterates Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) with a Buy and maintains $36 price target.

MBLY

Needham Reiterates Buy on Mobileye Global, Maintains $36 Price Target

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $97 price target.

BPMC

Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) with a Buy and maintains $15 price target.

LSTA

HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold.

SAGE

Needham Reiterates Hold on Sage Therapeutics

Wedbush's Dan Ives praised Microsoft Corp.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) performance after the company reported its <a href="https://www.benzinga.com/news/earnings/24/04/38444199/microsoft-q3-earnings-revenue-beat-eps-beat-new-era-of-ai-transformation-and-more">March 2024 quarter earnings</a> and beat revenue and earnings per share (EPS) estimates.
What Happened: Ives praised Microsoft CEO Satya Nadella for the company&#8217;s performance in the AI and cloud computing space.
Ives compared Nadella to a &#8220;grandmaster chess player&#8221; and lauded Microsoft&#8217;s Azure cloud platform for its growth in the AI sector. He also referred to the current state of AI as a &#8220;1995 Moment,&#8221; indicating a significant turning point in the industry.
See Also: <a href="https://www.benzinga.com/news/earnings/24/04/38452338/microsoft-alphabet-and-3-stocks-to-watch-heading-into-friday">Microsoft, Alphabet And 3 Stocks To Watch Heading Into Friday</a>
&#8220;For Nadella the grandmaster chess player another Picasso-like performance for Microsoft as Azure is firing on all cylinders and the AI Revolution plays out in front of our eyes. Our #1 AI Draft pick Microsoft hitting its next gear of growth."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">For Nadella the grandmaster chess player another Picasso-like performance for Microsoft as Azure is firing on all cylinders and the AI Revolution &#x1f525; plays out in front of our eyes. Our #1 AI Draft pick Microsoft hitting its next gear of growth. $500 PT &#x1f525;&#x1f3c6;&#x1f402;&#x1f37f;&#x1f576;&#xFE0F;. 1995 Moment &#x1f525;
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1783767713984164164?ref_src=twsrc%5Etfw">April 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ives reiterated a price target of $500 for Microsoft stock, which is currently up 4.25% in premarket trading on Friday, at $416, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
"Another historic night for Big Tech as the AI Revolution and this 1995 Moment is now here," Ives added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Another historic night for Big Tech as the AI Revolution and this 1995 Moment is now here <a href="https://twitter.com/CNBCClosingBell?ref_src=twsrc%5Etfw">@CNBCClosingBell</a> &#x1f525;&#x1f447; <a href="https://t.co/rN1kF6p9ZF">https://t.co/rN1kF6p9ZF</a>
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1783756944735371304?ref_src=twsrc%5Etfw">April 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Ives&#8217; comments come in the wake of Microsoft&#8217;s strong performance in the AI and cloud computing sector. During the third-quarter earnings call, Nadella <a href="https://www.benzinga.com/news/24/04/38450786/satya-nadella-says-azure-search-also-used-by-chatgpt-is-one-of-the-fastest-growing-services-for-micr">highlighted the strong demand for Azure</a>, particularly in the field of AI, which has significantly contributed to acquiring new customers.
Microsoft&#8217;s third-quarter revenue increased 17% year-over-year to $61.9 billion, which beat the consensus estimate of $60.804 billion. The tech giant reported quarterly earnings of $2.94 per share, which beat analyst estimates of $2.82 per share.
During the post-earnings call, <a href="https://www.benzinga.com/general/gaming/24/04/38451061/microsoft-ceo-satya-nadella-highlights-record-breaking-gaming-performance-expansion-to-nintendo-sw">Nadella also revealed</a> that Microsoft had set new records for game streaming hours, console usage, and monthly active devices.
Price Action: Microsoft's shares were up 4.25% in premarket trading on Friday, after closing at $399.04 on the previous day, according to Benzinga Pro.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next: <a href="https://www.benzinga.com/news/24/04/38426370/mark-zuckerberg-says-tens-of-millions-users-have-already-tried-meta-ai-and-people-are-asking-us-to-r">Mark Zuckerberg Says &#8216;Tens Of Millions&#8217; Users Have Already Tried Meta AI, And People Are &#8216;Asking Us To Release&#8230;Wherever They Are&#8217;</a>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Analyst Color

Equities

Tech

'Another Picasso-Like Performance:' Top Tech Analyst Praises Satya Nadella, Says Microsoft Is Top 'AI Draft Pick' With 20% Rally In Store

2024 Earnings&nbsp;Guidance
PGE is reaffirming its estimate for full-year 2024 adjusted earnings&nbsp;guidance&nbsp;of&nbsp;$2.98&nbsp;to&nbsp;$3.18&nbsp;per diluted share based on the following assumptions:
<ul>
<li>Exclusion of the impacts of the&nbsp;January 2024&nbsp;winter storm, including non-deferrable Reliability Contingency Event (RCE) costs and non-deferred incremental storm restoration costs;</li>
<li>An increase in energy deliveries of&nbsp;2%&nbsp;to&nbsp;3%, weather adjusted;</li>
<li>Normal temperatures in its utility service territory;</li>
<li>Hydro conditions for the year that reflect current estimates;</li>
<li>Wind generation based on five years of historical levels or forecast studies when historical data is not available;</li>
<li>Normal thermal plant operations;</li>
<li>Operating and maintenance expense between&nbsp;$815 million&nbsp;and&nbsp;$840 million&nbsp;which includes approximately&nbsp;$165 million&nbsp;of wildfire, vegetation management, deferral amortization and other expenses that are offset in other income statement lines;</li>
<li>Depreciation and amortization expense between&nbsp;$475 million&nbsp;and&nbsp;$525 million;</li>
<li>Effective tax rate of&nbsp;10%&nbsp;to&nbsp;15%;</li>
<li>Cash from operations of&nbsp;$700&nbsp;to&nbsp;$800 million;</li>
<li>Capital expenditures of&nbsp;$1,340&nbsp;million; and</li>
<li>Average construction work in progress balance of&nbsp;$795 million.</li>
</ul>

Guidance

Portland General Electric Reaffirms Its 2024 Guidance: Sees Adjusted EPS Of $2.98-$3.18 Vs. $3.07 Consensus, And Cash From Operations Of $700M-$800M

Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.09 by 11.01 percent. This is a 51.25 percent increase over earnings of $0.80 per share from the same period last year. The company reported quarterly sales of $940.000 million which beat the analyst consensus estimate of $828.972 million by 13.39 percent. This is a 26.17 percent increase over sales of $745.000 million the same period last year.

Earnings Beats

Portland Gen Electric Q1 2024 Adj EPS $1.21 Beats $1.09 Estimate, Sales $940.000M Beat $828.972M Estimate

Eric Melis, VP of Global Brand Marketing, Carbonated Soft Drinks at PepsiCo,&nbsp;said: &quot;Jack is renowned worldwide for his incredible football skills and the enjoyment he takes from the game. We celebrate those who personify our attitude on and off the pitch and can&#39;t wait for him to support us in bringing more enjoyment to football fans around the world as part of the Pepsi family.&quot;

PepsiCo Signs Football Star Jack Grealish As Global Brand Ambassador In Multi-year Partnership

TotalEnergies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) reported quarterly earnings of $2.14 per share which beat the analyst consensus estimate of $2.06 by 3.88 percent. The company reported $56.278 in sales this quarter. This is a 100.00 percent decrease over sales of $62.603 billion the same period last year.

TotalEnergies Q1 2024 Adj EPS $2.14 Beats $2.06 Estimate, Sales $56.278 Down From $62.603B YoY

<div>Underlying sales growth excluding OPM1&nbsp;and Strategic Review2&nbsp;of&nbsp;3%.</div>
<div>Strong operational progress in all divisions and continued execution momentum across our 2024 strategic priorities.</div>
<div>Continuing to infuse our products with AI and on-track to include AI features in more than 40 Higher Education titles for the Fall semester.</div>
<div>Initial &pound;300m share buyback completed; the previously announced &pound;200m buyback extension has commenced.</div>

Pearson Says It Will See Q1 Underlying Sales Growth Excluding OPM And Strategic Review Of 3%; On Track To Achieve 2024 Guidance With Expected Momentum For 2H

Car rental company&nbsp;Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) is now looking to remove 30,000 electric vehicles from its fleet, significantly higher than the number announced earlier this year.
What Happened: Earlier this year, Hertz announced that it is <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36606533/tesla-bulls-at-odds-after-hertzs-ev-selloff-blow-for-musks-company-or-black-eye-mom">looking to reduce its EV fleet by 20,000 units</a> through 2024, citing high repair costs as the driving factor. However, at the company&#8217;s first-quarter earnings call on Thursday, company COO Justin Keppy said that it has increased the EV disposal plan by another 10,000 units. 
As of the end of the first quarter, the company had already sold about 10,000 EVs, he said, on which it incurred vehicle depreciation costs of $195 million. 
&#8220;Upon completion, we anticipate that the remaining EV fleet will be better aligned with attractive demand for EVs with a priority on our rideshare business,&#8221; Keppy said.
See Also: <a href="https://www.benzinga.com/markets/equities/24/04/38107547/hertzs-mega-tesla-gamble-backfired-due-to-sky-high-repair-costs-unusually-high-accident-rates-an" target="_blank" rel="noreferrer noopener">Hertz&#8217;s Mega Tesla Gamble Backfired Due To Sky-High Repair Costs, Unusually High Accident Rates And Customers&#8217; Charging Anxiety</a> 
The decision to further reduce EVs within the fleet will help it align better with demand and lower operating costs, Keppy said. The company expects to see the benefits of reducing EVs from the fleet in the second half and for EVs deployed outside of rideshare to comprise just about 5% of its global fleet as of the end of 2024.
Why It Matters: <a href="https://www.benzinga.com/markets/equities/24/04/38434391/struggle-for-hertz-continues-as-stock-loses-23-heres-why">Hertz on Thursday reported</a> an adjusted loss of $1.28 per share, much higher than the analyst consensus estimate of a loss of 44 cents. 
"Fleet and direct operating costs weighed on this quarter's performance," said CEO Gil West. "We're tackling both issues – getting to the right supply of vehicles at an acceptable capital cost while at the same time driving productivity up and operating costs down."
Price Action: Hertz stock closed down 19.3% at $4.68 per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a> The stock is down 54.1% year-to-date. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/mobility" rel="noreferrer noopener">following this link</a>.
Read More: <a href="https://www.benzinga.com/news/24/04/38452299/tesla-ceo-elon-musk-denies-human-rights-abuses-in-most-ev-battery-production-those-that-do-use-very">Tesla CEO Elon Musk Denies Human Rights Abuses In Most EV Battery Production: &#8216;Those That Do&#8230;Use Very Little&#8217;</a>
Photo by EQRoy on Shutterstock

Another Blow To Tesla? Hertz's EV Disposal Plan Jumps By 10K As Car-Rental Company Aims For 95% Gas-Powered Fleet By Year-End

The latest update is out from Clene (CLNN). On February 29, 2024, the Company revealed exciting clinical results for its CNM-Au8 30mg treatment at ...

Clene Announces Breakthrough CNM-Au8 Treatment Results

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Clene (CLNN – Research Report), with a price target of $7.00. Joseph Pantgin...

Buy Rating Affirmed for Clene's CNM-Au8 on Promising Long-Term Clinical Outcomes

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Clene (CLNN – Research Report), REPRO-MED Systems (K...

Analysts Offer Insights on Healthcare Companies: Clene (CLNN), REPRO-MED Systems (KRMD) and Bioventus (BVS)

Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Clene (CLNN – Research Report), with a price target of $1.00. Naz Rahman has given his...

Buy Rating Affirmed for Clene Amid Positive ALS Drug Data and Market Dynamics

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX – Research Report),...

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Clene (CLNN) and Jazz Pharmaceuticals (JAZZ)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
When it comes to deciding whether you should acquire <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> or not, the answer is no. Okay, so we&rsquo;re done here, right?



Of course, human nature being what it is, people are going to place wagers. Fundamentally, the issue with penny stocks is that this segment really blurs the line between investment and legalized gambling. More often than not, people lose their shirts in this corridor of the equities market. You&rsquo;ve got to heed the warnings before you participate.



Nevertheless, the one aspect that keeps generations of investors piling into this arena is the law of small numbers. A tiny catalyst &ndash; whether rational or not &ndash; can lead to enormous gains in a short period of time. However, the opposite is also true. You can lose practically everything in a blink of an eye.



If you can accept this reality, maybe &ndash; just maybe &ndash; these penny stocks could be of interest to you.



<h2>Clene (CLNN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/penny-1600-300x169.jpg" alt="Pennies in a jar on top of a background of blurred pennies. Penny stocks."><div>Source: John Brueske / Shutterstock</div></div>Listed under the broad healthcare sector, Clene (NASDAQ:<a href="https://investorplace.com/stock-quotes/clnn-stock-quote/">CLNN</a>) is a biotechnology firm. Specifically, its clinical-stage pharmaceutical business focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Per its <a href="https://finance.yahoo.com/quote/clnn/profile">public profile</a>, Clene&rsquo;s lead drug is <a href="https://clene.com/pipeline/">CNM-Au8</a>, which is involved in various clinical trials addressing amyotrophic lateral sclerosis (ALS).



According to Spherical Insights, the global ALS treatment market size <a href="https://www.sphericalinsights.com/reports/amyotrophic-lateral-sclerosis-market#:~:text=Free%20Sample%20PDF-,The%20global%20Amyotrophic%20Lateral%20Sclerosis%20(ALS)%20Market%20is%20expected%20to,forecast%20period%202022%20to%202030.&amp;text=Amyotrophic%20lateral%20sclerosis%20(ALS)%20is,known%20as%20Lou%20Gehrig's%20disease.">may reach a valuation of $901.7 million by 2030</a>. If so, that would imply a compound annual growth rate (CAGR) of 6.2% from 2022. Given the fact that Clene&rsquo;s market capitalization is only a little bit above the nano-cap threshold of $50 million, on paper, there&rsquo;s tremendous upside potential for CLNN.



However, it&rsquo;s a tricky narrative. For the current fiscal year, experts believe that Clene will post a loss per share of 30 cents on revenue of $440,000. That&rsquo;s not exactly encouraging since last year, the company generated sales of $654,000.



Here&rsquo;s the thing: experts also believe that for fiscal 2025, revenue could clock in at $5.46 million. If so, we&rsquo;re talking a gargantuan growth rate, making CLNN a possibly worthwhile idea among penny stocks.



<h2>aTyr Pharma (LIFE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/penny-stocks-1600-300x169.jpg" alt="A concept image of a penny sitting on a stock chart"><div>Source: Billion Photos / Shutterstock.com</div></div>Another biotechnology firm, aTyr Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/life-stock-quote/">LIFE</a>) engages in the discovery and development of medicines based on novel immunological pathways. Its <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-expanded-access-program-eap-efzo-fittm">lead therapeutic candidate is efzofitimod</a>, a selective modulator that is in Phase 3 clinical trials for pulmonary sarcoidosis. The therapeutic is also in Phase 1b/2a trials for addressing other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease-related ILD.



According to Future Market Insights, the global lung disease therapeutics market was projected to reach a valuation of nearly $83.4 billion last year. Moreover, experts in the field believe that the segment <a href="https://www.futuremarketinsights.com/reports/chronic-lung-diseases-treatment-market">could hit $152.37 billion by 2033</a>. If so, that would represent a CAGR of 6.2%. Given the micro-cap profile of aTyr, speculators of penny stocks might have an intriguing opportunity with LIFE.



You know the drill. Even with the large total addressable market, aTyr is risky as you-know-what. However, analysts anticipate revenue in fiscal 2024 to land at $2.62 million. That would be 642.2% higher than last year&rsquo;s print of $353,000.



Not only that, they&rsquo;re looking for sales of $9.26 million in fiscal 2025. That would be 253.4% year-over-year growth, meaning LIFE is one of the penny stocks to watch.



<h2>Cybin (CYBN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/penny-stocks-300x169.png" alt="Stacks of pennies representing penny stocks. Nano-Cap Penny Stocks"><div>Source: John Brueske / Shutterstock.com</div></div>Yet another biotech enterprise, Cybin (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/cybn-stock-quote/">CYBN</a>) is a distinct player that should catch plenty of speculators&rsquo; attention. A clinical-stage biopharmaceutical firm, Cybin focuses on developing psychedelic-based therapeutics. According to its <a href="https://finance.yahoo.com/quote/cybn/profile">corporate profile</a>, the company&rsquo;s development pipeline includes <a href="https://cybin.com/cyb003/">CYB003, a deuterated psilocybin analog</a>, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders. It also has another drug candidate that addresses generalized anxiety disorders.



Based on data from Acumen Research and Consulting, the global psychedelic drugs market reached a valuation of $2.6 billion in 2022. By 2032, the sector <a href="https://www.acumenresearchandconsulting.com/psychedelic-drugs-market">could be worth $7.1 billion</a>, representing a CAGR of 10.9%. Moreover, as the medical community potentially embraces psychedelics to address certain conditions, this projection could turn out to be conservative.



Whatever the case, there&rsquo;s a lot of anticipation among market gamblers that CYBN could be a hidden-gem opportunity. As InvestorPlace contributor Tyrik Torres mentioned, it could be one of the <a href="https://investorplace.com/2024/03/3-high-potential-penny-stocks-to-turn-1000-into-1-million/">penny stocks to turn $1,000 into $1 million</a>.



What&rsquo;s really convincing is that CYBN carries a unanimous strong buy view among covering experts. As well, the average price target stands at $4.50. If you want a 10-bagger, this could be it.



Penny Stocks



On Penny Stocks and Low-Volume Stocks:&nbsp;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&nbsp;<a href="http://investorplace.com/">InvestorPlace.com</a>&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&nbsp;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">How to Profit Without Getting Scammed</a>



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/3-penny-stocks-that-could-be-multibaggers-in-the-making-march-edition/">3 Penny Stocks That Could Be Multibaggers in the Making: March Edition</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Penny Stocks That Could Be Multibaggers in the Making: March Edition

Clene (CLNN) has provided an announcement. A recent press release from the Company has revealed promising results for CNM-Au8 as a potential therap...

Clene Announces Breakthrough MS Therapy at Neurology Meeting

Clene stock rallies 52% post-market on MS drug data

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioNTech SE (BNTX – Research Report), Connect Biopha...

Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Wednesday!



Moving stocks this morning are earnings reports, acquisition plans, new drug data and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>INVO Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is rocketing more than 55% alongside its <a href="https://finance.yahoo.com/news/invo-reports-fourth-quarter-full-205900118.html">Q4 earnings report</a>.</li>



<li>Vanda Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/vnda-stock-quote/">VNDA</a>) shares are soaring over 38% on <a href="https://www.nasdaq.com/press-release/future-pak-confirms-proposal-to-acquire-vanda-pharmaceuticals-for-%247.25-to-%247.75-per">a firm acquisition proposal</a>.</li>



<li>VIA Optronics (NYSE:<a href="https://investorplace.com/stock-quotes/viao-stock-quote/">VIAO</a>) stock is surging more than 32% with heavy pre-market trading.</li>



<li>Clene (NASDAQ:<a href="https://investorplace.com/stock-quotes/clnn-stock-quote/">CLNN</a>) shares are rising over 26% on <a href="https://seekingalpha.com/news/4090283-clene-stock-rallies-post-market-on-ms-drug-data?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain%7Csection%3Aon-the-move">new drug data</a>.</li>



<li>Chromocell Therapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/chro-stock-quote/">CHRO</a>) stock is gaining more than 26% on an update to a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239123&amp;type=PDF&amp;symbol=CHRO&amp;cdn=722216dc7f57070dff83767fe9648f9d&amp;companyName=Chromocell+Therapeutics+Corporation&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-04-17">secondary stock offering</a>.</li>



<li>CXApp (NASDAQ:<a href="https://investorplace.com/stock-quotes/cxai-stock-quote/">CXAI</a>) shares are increasing over 26% with its <a href="https://www.marketwatch.com/story/cxapp-shares-rise-29-on-4q-2023-annual-recurring-revenue-growth-13f8abea">latest earnings report</a>.</li>



<li>Seelos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/seel-stock-quote/">SEEL</a>) stock is climbing more than 24% without any clear news on Wednesday morning.</li>



<li>Mobile Global Esports (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgam-stock-quote/">MGAM</a>) shares are getting a 22% boost as it <a href="https://investorplace.com/2024/04/why-is-mobile-global-esports-mgam-stock-down-18-today/">prepares for delisting</a>.</li>



<li>Gamer Pakistan (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/">GPAK</a>) stock is jumping 21% despite a lack of news today.</li>



<li>Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) shares are up over 19% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238318&amp;type=PDF&amp;symbol=GRTX&amp;cdn=6788b7c94daccbdc9a6c5412e270d44c&amp;companyName=Galera+Therapeutics+Inc.&amp;formType=SC+13G&amp;formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-04-16">shareholder stake update</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Trilogy Metals (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tmq-stock-quote/">TMQ</a>) stock is plummeting more than 22% <a href="https://www.nasdaq.com/press-release/trilogy-metals-provides-update-on-the-ambler-access-project-2024-04-17">following an update</a> to its Ambler Access Project.</li>



<li>Trio Petroleum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tpet-stock-quote/">TPET</a>) shares are diving over 20% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239194&amp;type=PDF&amp;symbol=TPET&amp;cdn=fb7a5495a316777660288b1087458323&amp;companyName=Trio+Petroleum+Corp.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-17">securing senior notes and a purchase agreement</a>.</li>



<li>Connexa Sports Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/yyai-stock-quote/">YYAI</a>) stock is tumbling more than 18% on Wednesday morning.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) shares are taking a close to 18% beating following a rally yesterday.</li>



<li>Ontrak (NASDAQ:<a href="https://investorplace.com/stock-quotes/otrk-stock-quote/">OTRK</a>) stock is sliding over 16% with the release of its <a href="https://finance.yahoo.com/news/ontrak-announces-2023-fourth-quarter-200500612.html">Q4 2023 earnings report</a>.</li>



<li>Dragonfly Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/dfli-stock-quote/">DFLI</a>) shares are retreating more than 16% <a href="https://investorplace.com/2024/04/why-is-dragonfly-energy-dfli-stock-up-56-today/">after rallying yesterday</a>.</li>



<li>Dynatronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/">DYNT</a>) stock is pulling back over 16% <a href="https://investorplace.com/2024/04/why-is-dynatronics-dynt-stock-up-93-today/">after rising on Tuesday</a>.</li>



<li>Ryvyl (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvyl-stock-quote/">RVYL</a>) shares are still falling more than 15% despite <a href="https://www.nasdaq.com/press-release/ryvyl-inc.-announces-cancellation-of-proposed-underwritten-public-offering-2024-04-16">canceling a proposed public offering</a>.</li>



<li>Hub Cyber Security (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/">HUBC</a>) stock is dropping over 14% <a href="https://investorplace.com/2024/04/why-is-hub-cyber-security-hubc-stock-up-35-today/">after a rally yesterday</a>.</li>



<li>iSun (NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/">ISUN</a>) shares close out our pre-market stock movers down more than 13% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238741&amp;type=PDF&amp;symbol=ISUN&amp;cdn=82f25393dbc89b776256155c3f0856b7&amp;companyName=iSun+Inc.&amp;formType=10-K&amp;formDescription=Annual+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-16">on an investor update</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-april-17th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

BNTX

CNTB

CYBN

GRTX

HUBC

ISUN

JAZZ

KRMD

LIFE

OTRK

PRAX

RVYL

SEEL

VNDA

YYAI

Press Releases

Clene Provides Update on ALS Clinical Development Meeting With FDA

General

Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension

Clene Inc. announces positive results from CNM-Au8 results from MS trial

Health Care

Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Clene to Present at the 36th Annual ROTH Conference

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Management

IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting